Please login to the form below

Not currently logged in
Email:
Password:

PRV

This page shows the latest PRV news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca buys FDA priority review voucher from Sobi

AstraZeneca buys FDA priority review voucher from Sobi

Sobi gained the PRV during the acquisition of Novimmune’s Gamifant (emapalumab) related business  earlier this year. ... The PRV is a useful tool to have in its arsenal for this therapy area.

Latest news

  • Tiziana joins type 1 diabetes prevention field Tiziana joins type 1 diabetes prevention field

    The share price of Provention Bio  doubled last month after it released data which showed its immunotherapy PRV-031 (teplizumab) could delay the onset of of type 1 diabetes in children

  • Type 1 diabetes prevention promise sends Provention Bio soaring Type 1 diabetes prevention promise sends Provention Bio soaring

    In comparison, the median time for PRV-031 (teplizumab)-treated participants to clinical diagnosis of T1D was just over 48 months. ... With PRV-031 (teplizumab), we may now be able to intervene and fundamentally change the progression of T1D for these

  • Alexion uses priority review voucher for Soliris follow-up Alexion uses priority review voucher for Soliris follow-up

    priority review voucher (PRV) to accelerate the FDA’s review. ... Alexion is sitting on a pair of PRVs awarded for earlier approvals for rare disease therapies (Strensiq and Kanuma), and it’s a measure of the importance the company attaches to

  • Sanofi pays $245m for FDA priority review voucher Sanofi pays $245m for FDA priority review voucher

    PRV reduces review time from ten to six months. Sanofi has bought another voucher that slices four months off the FDA review process, b ut hasn't yet said how it ... The French pharma major is paying small US drugmaker Retrophin $245m for the priority

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Licence. 145. Sarepta Therapeutics/  Gilead Sciences. PRV received when EXONDYS 51 was FDA approved for Duchenne muscular dystrophy. ... Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv

  • Pharma deals in August 2015 Pharma deals in August 2015

    In 2012 the PRV programme was extended to include rare pediatric diseases and the emergence of trading in PRVs was noted in our last annual Deal Watch report. ... Keeping this trend, United Therapeutics has sold a PRV to AbbVie for a headline value of

  • Pharma deals in May 2015 Pharma deals in May 2015

    The paediatric PRV was issued when Cholbam was approved for the treatment of patients with peroxismal disorders. ... 300. Retrophin/ Sanofi. Acquisition of priority review voucher [PRV]. For Cholbam [cholic acid] in bile acid disorders.

  • Pharma deals during November 2014 Pharma deals during November 2014

    BioMarin was awarded a Rare Pediatric Disease PRV when it received approval of Vimizim, a new biological product for patients with Mucopolysaccharidosis type IVA. ... Selling PRVs is a relatively new area and so these two deals provide initial benchmarks,

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics